Related Experiment Video
Updated: Aug 22, 2025

How to Use the H1 Deep Transcranial Magnetic Stimulation Coil for Conditions Other than Depression
Published on: January 23, 2017
Pentoxifylline as an adjunctive in treatment of negative symptoms in chronic schizophrenia: A double-blind,
Mahmoud S Abdallah1, Esraa M Mosalam2, Ahmed Hassan1
1Department of Clinical Pharmacy, Faculty of Pharmacy, University of Sadat City, Sadat City, Egypt.
Aim:
The aim of this study was to explore the effectiveness and safety of pentoxifylline as an adjuvant to risperidone in mitigating the negative symptoms in patients with chronic schizophrenia.
Methods:
In this randomized, placebo-controlled study, eighty outpatients with chronic schizophrenia were given risperidone for 8 weeks along with either pentoxifylline or a placebo. The positive and negative syndrome scale (PANSS) was used to assess patients at the start of the trial, as well as at 2, 4, 6, and 8 weeks. Pre- and posttreatment serum levels of cAMP, TNF-α-, and IL-6 were measured.
Results:
The pentoxifylline group revealed a significant effect for time-treatment interaction on PANSS-negative subscale scores (p < 0.001), PANSS general psychopathology subscale scores (p < 0.001), and PANSS total scores (p < 0.001), but not on PANSS-positive subscale scores (p = 0.169). Additionally, when compared to the placebo group, the pentoxifylline group demonstrated a statistically significant increase in cAMP serum level and a statistically significant decrease in TNF-α and IL-6 serum levels.
Conclusion:
Pentoxifylline adjunctive therapy with risperidone for 8 weeks was found to be promising in mitigating the negative symptoms in patients with chronic schizophrenia.
Trial Registration Number:
NCT04094207.
Related Concept Videos
Drug Therapy
Antianxiety Medications
Psychosis: Goals of Pharmacotherapy
Antidepressant Drugs: MAOIs and Other Agents
Negative and Cognitive Symptoms of Schizophrenia
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
Psychosis and Antipsychotic Drugs: Overview
Antipsychotic Drugs: Typical and Atypical Agents

